Top 3 Industries Ready to Take Off in 2015 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 1:34PM CST
The best way to narrow down your search for "big game" stocks in a volatile market is to resort to some expert advice like the Zacks Industry Rank.
TQNT: 27.72 (+0.50), CTP: 14.57 (-0.18), AMED: 28.97 (-0.08)
How to Invest Money: This Secret Could Save You Thousands
Brian Stoffel, The Motley Fool - Motley Fool - Mon Dec 22, 8:00AM CST
The secret of how to invest money is so simple these kids could get it right. Photo: Flickr user Mike King. Here at The Motley Fool, we try to avoid giving blanket advice on investing, because there are as many paths to financial independence as...
BEBE: 2.48 (-0.15), BIIB: 340.89 (+5.13), PSUN: 2.07 (+0.05), RECN: 16.41 (+0.22), VALU: 16.26 (+0.68), GRMN: 53.86 (+0.50), QSII: 15.73 (+0.23), AMED: 28.97 (-0.08), UMPQ: 17.28 (+0.06), YHOO: 50.65 (+0.63), RCL: 82.36 (+0.16), IART: 53.68 (+0.32), ATLC: 2.50 (+0.01), AEO: 13.53 (+0.02), ARMH: 46.80 (+0.46), CEB: 73.03 (+0.23), GPS: 41.46 (+0.09)
Uptrend Call Working As Amedisys Stock Rises 72.9% (AMED)
Comtex SmarTrend(R) - Wed Dec 17, 4:44PM CST
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on June 27th, 2014 at $16.00. In approximately 6 months, Amedisys has returned 72.95% as of today's recent price of $27.68.
AMED: 28.97 (-0.08)
DaVita to Merge Business Units, Advance Clinical Research - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 12:40PM CST
DaVita HealthCare Partners Inc.'s (DVA) business units ??? DaVita Clinical Research (DCR) and HealthCare Partners Clinical Research ??? are set to merge.
AFAM: 29.53 (-0.06), DVA: 76.06 (+0.07), AMED: 28.97 (-0.08), GTIV: 19.07 (unch)
New chief at Amedisys
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 8:39AM CST
AMED: 28.97 (-0.08)
Amedisys Board Names Paul B. Kusserow as New CEO
GlobeNewswire - Tue Dec 16, 7:37AM CST
Amedisys, Inc. (Nasdaq:AMED), a leading home health and hospice company, today announced that its Board of Directors has named Paul B. Kusserow as President and Chief Executive Officer and member of the Board of Directors. Kusserow will assume the role on December 16, 2014 from President and Interim CEO, Ronald LaBorde, who will remain a member of the senior management team in the role of Vice Chairman reporting directly to the CEO. LaBorde will also continue to serve as a member of the Board of Directors.
CNXR: 8.90 (+0.15), AMED: 28.97 (-0.08)
United States Home Health and Hospice Care Industry Analytics 2014-2021 - Market to reach $141 Billion by 2021
M2 - Mon Dec 15, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/8wh7p6/home_health_and) has announced the addition of Plunkett Research Ltd's new report "Home Health and Hospice Care Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 621600" to their offering. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Key Findings: - Home Health and Hospice Care Industry (U.S.) to reach $131.3 billion by 2021. - Home Health and Hospice Care Industry, including Average EBITDA, Operating Ratios and Sales per Employee. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - Addus Homecare Corp - Almost Family Inc - Amedisys Inc - American HomePatient Inc - Apria Healthcare Group Inc - BioScrip Inc - Chemed Corporation - Gentiva Health Services Inc - LHC Group Inc - Lincare Holdings Inc For more information visit http://www.researchandmarkets.com/research/8w...health_and Source: Plunkett Research Ltd
CHE: 106.16 (+0.13), AFAM: 29.53 (-0.06), LHCG: 30.33 (-0.21), BIOS: 6.37 (unch), AMED: 28.97 (-0.08), GTIV: 19.07 (unch)
Quest Diagnostics' Virus Test Kit Wins FDA Clearance Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 2:40PM CST
Studies conducted by Quest Diagnostics (DGX) over time have shown that the Simplexa test kit can offer fast, reliable results within an hour.
CHE: 106.16 (+0.13), AFAM: 29.53 (-0.06), DGX: 67.94 (-0.16), AMED: 28.97 (-0.08)
Amedisys Has Returned 67.9% Since SmarTrend Recommendation (AMED)
Comtex SmarTrend(R) - Wed Dec 10, 10:58AM CST
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on June 27th, 2014 at $16.01. In approximately 6 months, Amedisys has returned 67.89% as of today's recent price of $26.87.
AMED: 28.97 (-0.08)
Amedisys to Present at the 25th Annual Oppenheimer Healthcare Conference
GlobeNewswire - Wed Dec 10, 10:00AM CST
Amedisys, Inc. (Nasdaq:AMED), one of America's leading healthcare at home companies, today announced that Dale E. Redman, Interim Chief Financial Officer, will present at the 25 Annual Oppenheimer Healthcare Conference in New York, NY on Thursday, December 11, 2014.
AMED: 28.97 (-0.08)
The Right Time to Invest in Amedisys (AMED)? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 4:15PM CST
On Dec 8, 2014, we issued an updated research report on Amedisys Inc. (AMED).
CHE: 106.16 (+0.13), AFAM: 29.53 (-0.06), AMED: 28.97 (-0.08), GTIV: 19.07 (unch)
Why the P/S Ratio is My Favorite Valuation Metric - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Dec 09, 12:00AM CST
Why the P/S Ratio is My Favorite Valuation Metric - Screen of the Week
SYKE: 23.48 (-0.13), KR: 64.05 (-0.23), HA: 24.44 (+0.51), AMED: 28.97 (-0.08), CDW: 35.75 (+0.14)
Is Merge Healthcare (MRGE) a Buy after Strong Q3 Results? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 1:40PM CST
On Dec 5, 2014, we issued an updated research report on Merge Healthcare Incorporated (MRGE).
ICUI: 83.38 (+1.63), AMED: 28.97 (-0.08), MRGE: 3.59 (+0.05), OSUR: 10.26 (+0.25)
Shares of AMED Up 63.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 03, 9:36AM CST
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on June 27th, 2014 at $16.01. In approximately 5 months, Amedisys has returned 63.01% as of today's recent price of $26.09.
AMED: 28.97 (-0.08)
Market Has Not Yet Noticed Potential in Amedisys (AMED); Have You? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 7:32AM CST
One company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Amedisys Inc. (AMED).
AMED: 28.97 (-0.08)
Amedisys Up 62.6% Since SmarTrend Uptrend Call (AMED)
Comtex SmarTrend(R) - Wed Nov 26, 9:09AM CST
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on June 27th, 2014 at $16.01. In approximately 5 months, Amedisys has returned 62.57% as of today's recent price of $26.02.
AMED: 28.97 (-0.08)
Amedisys Inc. (AMED): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 7:32AM CST
This is because Amedisys Inc. (AMED) in the Medical-Outpatient space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
AMED: 28.97 (-0.08)
Comparing America's 3 Largest Home Health Care Companies
Joseph Cafariello - at Seeking Alpha - Fri Nov 21, 6:50AM CST
CHE: 106.16 (+0.13), AMED: 28.97 (-0.08), GTIV: 19.07 (unch)
Shares of AMED Up 56.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Nov 18, 4:47PM CST
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on June 27th, 2014 at $16.01. In approximately 5 months, Amedisys has returned 56.58% as of today's recent price of $25.06.
AMED: 28.97 (-0.08)